Pembrolizumab (Keytruda®), in combination with axitinib (Inlyta®), is indicated for the first-line treatment of advanced renal cell carcinoma (RCC) in adults.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||29/07/2019|
|Rapid review completed||23/08/2019|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab in combination with axitinib compared with the current standard of care.|